Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
This research investigates the safety and tolerability of three different dose schedules of budoprutug, a humanized monoclonal antibody targeting CD19, in adults with primary membranous nephropathy PMN who test positive for anti-PLA2R antibodies and continue to have proteinuria despite optimized RAAS inhibitor treatment. The Phase 2, open-label, multicenter study aims to assess how this drug affects the immune system and kidney function in this condition. Participants will receive budoprutug intravenously on four specific days Day 1, Day 15, Day 169, and Day 183. The study includes three sequential groups, each receiving a different dose level of budoprutug. After dosing, participants will be followed for a total of 48 weeks to monitor safety and drug effects, with extended follow-up as needed to observe the recovery of B cells. During the study, participants will undergo assessments including blood tests to monitor B cell counts, anti-PLA2R antibody levels, kidney function eGFR, proteinuria, and urine albumin-to-creatinine ratio. Researchers will track any adverse events throughout the 48 weeks and evaluate the drugs pharmacokinetics. The total study participation lasts up to 48 weeks, with additional follow-up if necessary to ensure safety and recovery monitoring.
Actively Recruiting
Researchers are evaluating the antiviral effects of various treatments in adults aged 18 to 60 with early symptomatic influenza. This phase 2, multi-centre, adaptive platform trial compares several licensed influenza antiviral drugs and others with potential activity against the virus. The study aims to provide clear comparisons of antiviral activity to help guide treatment decisions and policy development. Participants may receive one of several antiviral drugs such as oseltamivir, favipiravir, zanamivir, baloxavir, molnupiravir, peramivir, laninamivir, or combinations of these medications. There is also a control group that receives no antiviral treatment except paracetamol for fever. Dosages and administration routes vary by drug and include oral, inhaled, and intravenous methods. The trial uses randomization to assign treatments, with at least 20% of participants assigned to the no treatment group. During the first five days, researchers will monitor the rate of viral clearance to assess antiviral activity. Additional measures include symptom relief and fever duration over 14 days. Participants will be closely followed up, with assessments including rapid antigen or PCR tests for influenza, symptom tracking, and safety monitoring. The total study period covers initial treatment and observation up to two weeks after starting treatment.
Actively Recruiting
This research aims to evaluate the effectiveness and safety of zanidatamab combined with a physicians choice of chemotherapy compared to trastuzumab combined with chemotherapy in treating adults with metastatic HER2-positive breast cancer who have either progressed on or cannot tolerate previous trastuzumab deruxtecan T-DXd treatment. Zanidatamab has shown promising results against various HER2-positive advanced tumors, including metastatic breast cancer, and may serve as a potential treatment option for these patients. The study also investigates patient-reported tolerability and physical functioning, as well as the pharmacokinetics and immune response to zanidatamab with chemotherapy. Participants will be randomly assigned to receive either zanidatamab or trastuzumab, each given by intravenous infusion alongside one of several chemotherapy options chosen by the physician eribulin, vinorelbine, gemcitabine, or capecitabine the latter is taken orally. Treatment will be administered according to the assigned group, and the study is open-label and multicenter, designed to compare these two treatment combinations in this patient population. During the study, participants will undergo regular assessments to monitor disease progression using imaging criteria RECIST version 1.1, evaluate survival, treatment response, and duration of response. Safety and side effects will be tracked through adverse event reporting and patient questionnaires on symptoms and physical function. Blood samples will be collected to study drug levels and immune reactions. Participants will be followed until disease progression, death, or for up to approximately 44 months for key outcomes, with overall survival monitored for up to about 80 months.
Actively Recruiting
Researchers are evaluating Debio 4126, a 12-week extended-release formulation of octreotide, for treating adults with acromegaly who have previously been treated with somatostatin analogs. The main goal is to assess how well Debio 4126 maintains insulin-like growth factor 1 IGF-1 levels at or below the upper limit of normal ULN during a 36-week double-blind period compared to a placebo. This Phase 3 trial involves participants whose acromegaly is stable on prior treatment and meets specific health requirements. During the first 36 weeks Period 1, participants receive either Debio 4126 or a placebo via intramuscular injection every 12 weeks, totaling three injections. Participants whose IGF-1 levels remain controlled may continue into Period 2, where all receive open-label Debio 4126 injections every 12 weeks for an additional 24 to 60 weeks. Rescue medication is available if acromegaly is not well controlled, and dosing continues based on IGF-1 levels and response. Throughout the study, participants undergo regular assessments including IGF-1 monitoring, safety evaluations, and examination of injection site tolerability. Researchers measure the percentage of participants maintaining IGF-1 at or below ULN, changes in growth hormone levels, treatment-emergent adverse events, and plasma concentrations of Debio 4126 over up to 108 weeks. The study includes safety monitoring and allows for long-term follow-up to evaluate treatment effects.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults with chronic heart failure who have a reduced left ventricular ejection fraction below 40%. Participants must have been diagnosed with chronic heart failure for at least three months and be in New York Heart Association classes II to IV. The study is a phase III, randomized, double-blind trial aimed at assessing whether this combination improves outcomes compared to placebo plus empagliflozin. Participants are randomly assigned to one of two groups with equal chance one group receives vicadrostat with empagliflozin tablets, and the other receives placebo with empagliflozin tablets. The study medicines are taken once daily for about six months up to three and a half years. Participants continue their regular heart failure treatments alongside the study drugs. The study monitors participants throughout this period, which can last up to 43 months. During the study, participants attend regular visits to the study site and may receive some follow-up calls. They answer questionnaires about their symptoms and overall well-being. Doctors record any worsening heart failure symptoms, hospitalizations due to heart failure, or deaths to compare the two groups. Health status and any side effects are regularly checked. The primary outcome is the time to first cardiovascular death, hospitalization for heart failure, or urgent heart failure visit.
Actively Recruiting
This research investigates the effectiveness and safety of tisagenlecleucel therapy in patients with B-cell malignancies in Brazil. It includes both children and adults with relapsed or refractory B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, or follicular lymphoma. The study is prospective and observational, aiming to collect long-term data over up to 15 years after treatment to understand outcomes in real-world settings. Participants include pediatric patients under 18 years with B-cell acute lymphoblastic leukemia, young adults aged 18-25 with the same diagnosis, and adults 18 or older with diffuse large B-cell lymphoma or follicular lymphoma. All patients have received tisagenlecleucel therapy either commercially or as out-of-specification use. The study does not involve administering treatment or mandating questionnaires instead, it monitors patients before and after infusion to gather comprehensive data. Participants information will be collected from diagnosis through to years after infusion, including response rates, survival, and safety events. Researchers will track overall response, relapse-free survival, and other health outcomes up to 15 years. Data will include retrospective and prospective information until death or last visit. Safety events, pregnancy rates, and secondary malignancies will also be monitored throughout the study period.
Actively Recruiting
Researchers are evaluating antiviral treatments for adults with early symptomatic COVID-19 who have high viral loads but are at low risk of severe illness. This Phase 2 trial aims to develop and validate a way to measure how well these treatments reduce the amount of virus in the body. The study compares three types of interventionssmall molecule drugs, monoclonal antibodies, and dose adjustments for nirmatrelvirritonaviragainst a control group that receives no antiviral treatment. The trial is adaptive and is supported by the Wellcome Trust through the COVID-19 Therapeutics Accelerator. The treatments studied include various small molecule drugs like nitazoxanide, nirmatrelvirritonavir, hydroxychloroquine, atilotrelvirritonavir, metformin, and monoclonal antibodies such as sotrovimab and others as they become available. Some treatment arms have been closed after meeting stopping criteria. Participants are randomly assigned to receive one of the available antiviral drugs or no treatment, with at least 20% assigned to the control group. Dosages vary by drug and are typically administered over 5 to 7 days. Participants will be monitored closely over the first 14 days, with daily assessments of viral levels and symptoms. Researchers will measure how quickly the virus clears from the body compared to no treatment or positive control arms. Additional outcomes include fever resolution and symptom improvement. Participants must be able to walk unaided and agree to follow-up visits. The study runs until January 2027 and aims to determine optimal dosing and antiviral effectiveness in early COVID-19 infection.
Actively Recruiting
Researchers are conducting an observational, multicenter, international study to learn about antimicrobial resistance AMR in people with chronic lung diseases CLD worldwide. The study aims to understand how common AMR is in these patients, how it varies by location, and what risk factors contribute to it. This study is non-pharmacological and collects data without adding any new treatments or procedures beyond usual care. Data will be collected at multiple centers during two separate two-week periods each year for five years. Participants include patients of all ages with chronic lung diseases who have had at least one respiratory sample collected within the past year. Clinical, demographic, and microbiological information will be gathered through questionnaires and medical records, all recorded in a secure electronic system. No additional tests or interventions outside routine clinical practice will be performed. Participants will provide informed consent before joining. Throughout the study, researchers will monitor the prevalence of antimicrobial resistance and analyze susceptibility patterns of key resistant pathogens, geographical differences, and risk factors for AMR by reviewing collected clinical and microbiological data. The study will last five years, with data collected periodically and securely maintained to better understand AMRs impact on chronic lung diseases.
Actively Recruiting
Researchers are studying the effects of early intensive antiretroviral therapy ART with or without broadly neutralizing antibodies on achieving HIV remission in infants living with HIV. This phase III study includes two groups infants born to mothers with limited or no antiretroviral use during pregnancy and infants diagnosed with HIV within 48 hours of birth who start ART immediately. The goal is to see if early treatment can suppress HIV to undetectable levels. Participants will receive one of seven intensive ART regimens combining nucleoside reverse transcriptase inhibitors NRTIs with drugs like nevirapine, lopinavirritonavir, raltegravir, dolutegravir, and monoclonal antibodies VRC01 or VRC07-523LS. Therapy begins within 48 hours of birth and may include switches in medication based on age and weight. The study has four steps initial evaluation and therapy start, up to 192 weeks of treatment with monitoring, possible treatment interruption for those with sustained viral suppression, and re-initiation of ART if viral rebound occurs. During the study, infants undergo regular HIV testing, safety monitoring, and immune assessments. Researchers track how many achieve HIV remission by week 48 and monitor viral suppression and adverse events through week 192. If treatment interruption is attempted, participants are closely observed for viral rebound for up to ten years, followed by monitoring after ART re-initiation until age five or six months after viral suppression. The entire study may last several years to evaluate long-term outcomes.